KR20220018822A - Composition for preventing and treating osteoporosis comprising extracts of fermented tenebrio molitor larva - Google Patents
Composition for preventing and treating osteoporosis comprising extracts of fermented tenebrio molitor larva Download PDFInfo
- Publication number
- KR20220018822A KR20220018822A KR1020200099392A KR20200099392A KR20220018822A KR 20220018822 A KR20220018822 A KR 20220018822A KR 1020200099392 A KR1020200099392 A KR 1020200099392A KR 20200099392 A KR20200099392 A KR 20200099392A KR 20220018822 A KR20220018822 A KR 20220018822A
- Authority
- KR
- South Korea
- Prior art keywords
- fermented
- extract
- composition
- osteoporosis
- present
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 41
- 241000254109 Tenebrio molitor Species 0.000 title abstract description 4
- 210000002997 osteoclast Anatomy 0.000 claims abstract description 21
- 210000000963 osteoblast Anatomy 0.000 claims abstract description 14
- 235000013376 functional food Nutrition 0.000 claims abstract description 13
- 230000001737 promoting effect Effects 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 238000000855 fermentation Methods 0.000 claims description 16
- 230000004151 fermentation Effects 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 13
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 32
- 235000013305 food Nutrition 0.000 abstract description 22
- 210000004027 cell Anatomy 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 230000004069 differentiation Effects 0.000 description 15
- 238000000605 extraction Methods 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 210000000988 bone and bone Anatomy 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 8
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- -1 for example Substances 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 230000037182 bone density Effects 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000004072 osteoblast differentiation Effects 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000003262 anti-osteoporosis Effects 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000005445 natural material Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 241000235070 Saccharomyces Species 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 238000001794 hormone therapy Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 241000877401 Saccharomyces ellipsoideus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010070918 Bone deformity Diseases 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 241001063879 Saccharomyces eubayanus Species 0.000 description 1
- 241001123227 Saccharomyces pastorianus Species 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008126 dulcin Substances 0.000 description 1
- NWNUTSZTAUGIGA-UHFFFAOYSA-N dulcin Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(O)CC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NWNUTSZTAUGIGA-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 210000001721 multinucleated osteoclast Anatomy 0.000 description 1
- 230000020395 negative regulation of osteoclast differentiation Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 208000002865 osteopetrosis Diseases 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229940086065 potassium hydrogentartrate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000019617 pupation Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
Abstract
Description
본 발명은 갈색거저리 유충 발효 추출물을 포함하는 골다공증의 예방 또는 치료용 조성물, 골다공증의 예방 및 개선에 대한 기능성 식품에 관한 것이다.The present invention relates to a composition for preventing or treating osteoporosis, comprising a fermented extract of Mealworm larvae, and functional food for preventing and improving osteoporosis.
골다공증이란 뼈의 주성분인 칼슘이 급격히 빠져나와 정상적인 뼈에 비하여 골밀도가 낮아져 "구멍이 많이 난 뼈"를 말하며, 폐경, 노화, 뼈에 해로운 약물의 사용 등의 여러 가지 원인에 의하여 뼈가 많이 손실되고 약해져 경미한 충격에도 쉽게 골절이 일어나는 질환이다.Osteoporosis refers to "perforated bone" due to the rapid loss of calcium, the main component of bone, and lower bone density than normal bone. It is a disease in which fractures occur easily even with a slight impact.
갱년기가 되면 뼈의 대사에 중요한 역할을 하는 여성호르몬이 더 이상 난소에서 분비되지 않기 때문에 이런 골 교체에 변화가 나타나서 파골세포가 녹인 부위를 조골세포가 새로운 뼈를 만들어 채우기는 하지만 완전히 채우지 못하고 골 손실이 일어난다.At menopause, as female hormones, which play an important role in bone metabolism, are no longer secreted by the ovaries, this change in bone replacement occurs. this happens
소위 갱년기에 접어든 여성의 약 60% 정도에서 발생하고(제1형 골다공증) 인체의 노화로 인한 전체적 대사작용의 저하로 골밀도가 떨어져서 생기는 경우(제2형 골다공증)도 있다. 골다공증을 치료하지 않고 방치해두면 요통, 허리가 구부러지게 되는 신체의 변형, 신장의 감소, 전신쇠약, 무기력 등에 시달리게 되고, 골절로 인해 큰 고통을 당하게 된다.It occurs in about 60% of so-called menopause women (
골다공증 치료제로 널리 사용되는 칼슘 보강 제재가 최근에 그 효과가 충분하지 못함이 보고되었으며 에스트로젠이나 칼시토닌을 이용한 호르몬 요법에 있어서도 역시 치료효과가 충분하지 못함이 알려지고 있다. 특히 에스트로젠이나 칼시토닌을 이용한 호르몬 요법은 장기 투여시 간, 난소, 유방 등에 종양을 일으키는 부작용을 일으키기도 한다. 이와 관련하여, 호르몬 요법을 보완하는 연구들이 보고된 바 있으나(RL. Prince, et. al., N. Engl. J. Med., 325(17):1189-1195, 1991), 여전히 안전한 천연물 소재를 이용한 골다공증 치료 물질이 필요가 충족되지 못한 상황이다.Calcium supplementation agents widely used for osteoporosis treatment have recently been reported to be ineffective, and hormone therapy using estrogen or calcitonin is also known to have insufficient therapeutic effect. In particular, hormone therapy using estrogen or calcitonin may cause side effects that cause tumors in the liver, ovaries, and breasts when administered for a long period of time. In this regard, studies that supplement hormone therapy have been reported (RL. Prince, et. al. , N. Engl. J. Med. , 325(17):1189-1195, 1991), but still safe natural ingredients The need for osteoporosis treatment materials using
한편, "갈색거저리(Tenebrio molitor)"는 딱정벌레목 거저리과의 곤충으로, 몸길이는 약 15 ㎜정도이며, 어두운 갈색이며 광택이 난다. 갈색거저리의 유충은 밀웜(mealworm)이라 하여 먹이곤충이나 애완용으로 많이 사육하는데, 밀웜이 애완용으로 이용되는 이유는 변태기간이 비교적 짧아 곤충을 쉽게 체험할 수 있고 곡식을 먹이로 하는 매우 청결한 곤충이기 때문이다. 유충은 번데기가 되기까지 먹이와 온도에 따라 9~20번 탈피한다. 번데기가 되고 2~3주가 지나면 성충으로 우화하며 처음으로 우화할 때에는 연한 갈색이나 점차 검게 변한다. 성충은 야행성으로 낮에는 구멍 속에 숨어 지내다가 밤에 활동한다. 주로 인가 근처의 곡식부대 속에서 유충으로 월동하다가 봄에 번데기와 성충으로 변태한다.On the other hand, "brown mealworm ( Tenebrio molitor )" is an insect of the Coleoptera family Mealuridae, with a body length of about 15 mm, dark brown and glossy. Caterpillars of brown mealworm are called mealworms and are often bred as food insects or pets. to be. Caterpillars molt 9 to 20 times depending on food and temperature until they pupate. After 2~3 weeks after pupation, it emerges as an adult, and when it first emerges, it is light brown but gradually turns black. Adults are nocturnal, hiding in holes during the day and active at night. It mainly overwinters as larvae in grain sacks near in-houses, then metamorphoses into pupae and adults in spring.
이러한 갈색거저리는 곤충 중에서 단백질 함량이 제일 높고 지방함량이 낮아 단백질 보급원으로 매우 효과적이라는 보고가 있으며, 특히 항암물질들과 함께 간암세포주에 처리되었을 때 증대되는 항암활성을 나타낸다고 알려져 있다.Among insects, brown mealworm has the highest protein content and low fat content, so it is reported that it is very effective as a protein supply source.
이러한 갈색거저리의 용도와 관련된 특허로 한국등록특허 제10-1651908호에 갈색거저리 유충 또는 이의 추출물을 유효성분으로 포함하는 당뇨 예방 또는 치료용 조성물이 개시되어 있으며, 한국등록특허 제10-1651907호에는 갈색거저리 유충의 추출물 또는 갈색거저리 유충의 현탁액을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물이 개시되어 있다. 또한, 한국등록특허 제10-1424125호에 갈색거저리 유충을 포함하는 염증성 질환 치료용 조성물이 개시되어 있고, 한국등록특허 제10-1404566호에는 갈색거저리 추출물을 포함하는 치매 예방 또는 치료용 조성물에 대해 개시되어 있다. 그러나, 아직까지 갈색거저리를 이용한 항골다공증 효과에 관해서는 보고된 바가 없다.As a patent related to the use of such brown mealworm, Korean Patent Registration No. 10-1651908 discloses a composition for preventing or treating diabetes comprising brown mealworm larvae or an extract thereof as an active ingredient, and Korean Patent No. 10-1651907 Disclosed is a composition for preventing or treating obesity comprising an extract of mealworm larvae or a suspension of mealworm larvae as an active ingredient. In addition, Korean Patent No. 10-1424125 discloses a composition for treating inflammatory diseases containing mealworm larvae, and Korean Patent No. 10-1404566 discloses a composition for preventing or treating dementia comprising an extract of Mealworm Mealworm. has been disclosed. However, there has been no report on the anti-osteoporosis effect of brown mealworm.
이에, 본 발명자들은 골다공증 치료 효과를 가지는 천연물 유래 소재를 개발하고자 연구 노력한 결과, 갈색거저리 유충 발효 추출물의 파골세포 활성 억제 효과와 조골세포 활성 촉진 효과를 확인하여 본 발명을 완성하였다.Accordingly, the present inventors completed the present invention by confirming the osteoclast activity inhibitory effect and osteoblast activity promoting effect of the brown mealworm larva ferment extract as a result of research efforts to develop a natural material-derived material having an osteoporosis treatment effect.
본 발명의 목적은 갈색거저리 유충 발효 추출물을 유효성분으로 포함하는 골다공증 예방 또는 치료용 약학적 조성물을 제공하기 위한 것이다.It is an object of the present invention to provide a pharmaceutical composition for preventing or treating osteoporosis comprising a fermented brown mealworm larvae extract as an active ingredient.
본 발명의 다른 목적은 갈색거저리 유충 발효 추출물을 유효성분으로 포함하는 골다공증 예방 또는 개선용 건강기능식품 조성물을 제공하기 위한 것이다.Another object of the present invention is to provide a health functional food composition for preventing or improving osteoporosis comprising a fermented brown mealworm larvae extract as an active ingredient.
본 발명의 또 다른 목적은 갈색거저리 유충 발효 추출물을 인간을 제외한 개체에 투여하는 단계를 포함하는 골다공증 예방 또는 치료 방법을 제공하기 위한 것이다.Another object of the present invention is to provide a method for preventing or treating osteoporosis, comprising administering a fermented brown mealworm larvae extract to individuals other than humans.
상기 목적을 달성하기 위해, 본 발명은 갈색거저리 유충 발효 추출물을 유효성분으로 포함하는 골다공증 예방 또는 치료용 약학적 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating osteoporosis comprising a fermented brown mealworm larvae extract as an active ingredient.
또한, 본 발명은 갈색거저리 유충 발효 추출물을 유효성분으로 포함하는 골다공증 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for preventing or improving osteoporosis comprising a fermented brown mealworm larvae extract as an active ingredient.
아울러, 본 발명은 갈색거저리 유충 발효 추출물을 인간을 제외한 개체에 투여하는 단계를 포함하는 골다공증 예방 또는 치료 방법을 제공한다.In addition, the present invention provides a method for preventing or treating osteoporosis comprising administering the fermented extract of Mealworm larvae to individuals other than humans.
본 발명에 따른 갈색거저리 유충 발효 추출물을 포함하는 예방 또는 치료용 약학적 조성물은 파골세포를 억제하는 동시에 조골세포를 촉진하는 효과를 나타내어 골다공증에 우수한 치료 효과를 가지며 정상 세포에 낮은 독성을 가지므로 예방 또는 치료용 약학적 조성물, 기능성 식품의 활성 성분으로 제공될 수 있다.The preventive or therapeutic pharmaceutical composition comprising the fermented brown mealworm larvae extract according to the present invention has an excellent therapeutic effect on osteoporosis and has low toxicity to normal cells by inhibiting osteoclasts and promoting osteoblasts at the same time. Or it may be provided as an active ingredient of a pharmaceutical composition for treatment or functional food.
도 1은 본 발명의 갈색거저리 유충 발효 추출물이 파골세포 분화에 미치는 영향을 확인한 도이다. 상세하게는, 갈색거저리 유충 발효 추출물에 의한 파골세포 분화 억제 정도를 TRAP 염색하여 관찰한 결과를 나타낸 현미경 사진이다.
도 2는 본 발명의 갈색거저리 유충 발효 추출물이 조골세포 분화에 미치는 영향을 확인한 도이다. 상세하게는, 갈색거저리 유충 발효 추출물에 의한 조골세포 분화 촉진 정도를 ALP 염색하여 관찰한 결과를 나타낸 현미경 사진이다.1 is a view confirming the effect of the brown mealworm larvae fermented extract of the present invention on osteoclast differentiation. In detail, it is a micrograph showing the results of observation by TRAP staining of the degree of inhibition of osteoclast differentiation by the fermented extract of Mealworm larvae.
Figure 2 is a view confirming the effect of the brown mealworm larvae ferment extract of the present invention on osteoblast differentiation. In detail, it is a photomicrograph showing the results of observation by ALP staining of the degree of promotion of osteoblast differentiation by the brown mealworm larva ferment extract.
본 발명은 갈색거저리 유충 발효 추출물을 포함하는 골다공증의 예방 또는 치료용 조성물, 골다공증의 예방 및 개선에 대한 기능성 식품에 관한 것으로, 갈색거저리 유충 발효 추출물이 파골세포를 억제하는 동시에 조골세포를 촉진하는 효과를 나타내므로, 골다공증을 예방, 개선 또는 치료에 유용하게 이용될 수 있다.The present invention relates to a composition for the prevention or treatment of osteoporosis, comprising a fermented extract of mealworm larvae, and a functional food for the prevention and improvement of osteoporosis. Therefore, it can be usefully used for preventing, improving or treating osteoporosis.
하나의 양태로서, 본 발명은 갈색거저리 유충 발효 추출물을 유효성분으로 포함하는 골다공증 예방 또는 치료용 약학적 조성물을 제공한다.In one aspect, the present invention provides a pharmaceutical composition for preventing or treating osteoporosis comprising a fermented brown mealworm larvae extract as an active ingredient.
본 발명에 있어서, "갈색거저리 유충 발효 추출물"은 갈색거저리 유충을 유기용매를 이용하여 추출하여 갈색거저리 유충에 함유된 유지 및 지방 성분을 제거한 다음 건조하고, 효모 균주를 이용하여 발효시킨 다음 물 또는 유기 용매를 이용하여 추출함으로써 수득될 수 있다.In the present invention, "Brown mealworm larva ferment extract" is extracted using an organic solvent to remove the oil and fat components contained in Mealworm larvae of Brown Mealtimes, then dried, fermented using yeast strain, and then water or It can be obtained by extraction using an organic solvent.
본 발명의 구체적인 실시양태에 따르면, 상기 갈색거저리에 함유된 유지 및 지방 성분 제거는 유기용매 예를 들어, 물, 메탄올, 에탄올, 이소프로판올, 부탄올, 에틸렌, 아세톤, 헥산, 에테르, 클로로포름, 에틸아세테이트, 부틸아세테이트, 디클로로메탄, N,N-디메틸포름아미드(DMF), 디메틸설폭사이드(DMSO), 1,3-부틸렌글리콜, 프로필렌글리콜 또는 이들의 혼합용매를, 바람직하게는 헥산을 이용하여 20 내지 30 시간, 바람직하게는 23 내지 25시간 추출하여 수행될 수 있다.According to a specific embodiment of the present invention, the oil and fat components contained in the brown mealworm are removed using an organic solvent such as water, methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, Butyl acetate, dichloromethane, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol or a mixed solvent thereof, preferably using hexane 20 to It may be carried out by extraction for 30 hours, preferably 23 to 25 hours.
본 발명의 구체적인 실시양태에 따르면, 상기 발효는 유지 및 지방 성분이 제거된 갈색거저리 유충에 효모 균주를 접종한 다음 20 내지 40℃, 바람직하게는 23 내지 35℃에서 60 내지 80 시간, 바람직하게는 70 내지 75 시간 동안 배양하는 것이다. 발효 온도가 20℃ 미만인 경우에는 발효가 충분히 일어나지 않거나 발효에 오랜 시간이 소요되므로 비효율적이고, 발효 온도가 40℃ 초과하는 경우 효모 균주의 활성이 저하될 수 있어 발효가 충분히 일어나지 않을 수 있다. 또한 발효 시간이 60시간 미만인 경우에는, 갈색거저리 유충의 발효가 충분히 일어나지 않아 제조된 갈색거저리 유충 발효 추출물이 항골다공증 효과를 충분히 발휘할 수 없으며, 발효 시간이 80시간을 초과하는 경우에는, 그 이하의 시간 동안 발효하는 것과 발효 효율에 차이가 없어 비경제적이다.According to a specific embodiment of the present invention, the fermentation is performed by inoculating a yeast strain on brown mealworm larvae from which oils and fats have been removed, and then at 20 to 40° C., preferably 23 to 35° C., for 60 to 80 hours, preferably Incubation for 70 to 75 hours. If the fermentation temperature is less than 20 ℃, fermentation does not occur sufficiently or it takes a long time for fermentation, so it is inefficient, and if the fermentation temperature exceeds 40 ℃, the activity of the yeast strain may decrease, so that the fermentation may not occur sufficiently. In addition, if the fermentation time is less than 60 hours, the fermentation of the brown mealworm larvae does not sufficiently occur, so the prepared brown mealworm larvae fermented extract cannot sufficiently exhibit the antiosteoporotic effect. It is uneconomical because there is no difference in fermentation efficiency from fermentation for a period of time.
상기 효모 균주는 예를 들어 사카로마이세스 세레비지애(Saccharomyces cerevisiae) 균주, 사카로마이세스 엘립소이데우스(S. ellipsoideus), 사카로마이세스 오베야누스(S. eubayanus), 사카로마이세스 파스토리아누스(S. pastorianus), 사카로마이세스 플로렌티누스(S. florentinus) 등을 들 수 있으며, 바람직하게는 사카로마이세스 세레비지애(Saccharomyces cerevisiae) 균주를 사용한다.The yeast strain is, for example, Saccharomyces cerevisiae ( Saccharomyces cerevisiae ) strain, Saccharomyces ellipsoideus ( S. ellipsoideus ), Saccharomyces obeyanus ( S. eubayanus ), Saccharomyces pars Torianus ( S. pastorianus ), Saccharomyces florentinus ( S. florentinus ) and the like, and preferably Saccharomyces cerevisiae ( Saccharomyces cerevisiae ) strain is used.
본 발명의 구체적인 실시양태에 따르면, 상기 갈색거저리 유충 발효물의 추출은 물 또는 유기용매, 예를 들어 물, 메탄올, 에탄올, 이소프로판올, 부탄올, 에틸렌, 아세톤, 헥산, 에테르, 클로로포름, 에틸아세테이트, 부틸아세테이트, 디클로로메탄, N,N-디메틸포름아미드(DMF), 디메틸설폭사이드(DMSO), 1,3-부틸렌글리콜, 프로필렌글리콜 또는 이들의 혼합용매를 사용하여 열수, 냉침 추출, 초음파 추출, 환류 냉각 추출 등의 방법으로 수행할 수 있으며, 구체적으로 본 발명에서는 갈색거저리 유충 발효물을 물 또는 60 내지 100% 주정을 이용하여 가열, 비가열 또는 냉침 추출할 수 있다.According to a specific embodiment of the present invention, the extraction of the fermented mealworm larvae is water or an organic solvent, for example, water, methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate. , dichloromethane, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixture thereof using hot water, cold extraction, ultrasonic extraction, reflux cooling It can be carried out by a method such as extraction, and specifically, in the present invention, the fermented mealworm larvae can be heated, unheated or cold-extracted using water or 60 to 100% alcohol.
또한, 상기 갈색거저리 유충 발효 추출물은 상기 추출용매에 의하여 추출하는 방법 외에 통상적인 정제과정을 거쳐서도 수득할 수 있다. 예컨대, 일정한 분자량 컷-오프 값을 갖는 한외여과막을 이용한 분리, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제방법을 통해 얻어진 분획을 통하여서도 갈색거저리 유충 발효 추출물을 수득할 수 있다.In addition, the fermented brown mealworm larvae extract can be obtained through a conventional purification process in addition to the extraction method using the extraction solvent. For example, separation using an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (prepared for separation according to size, charge, hydrophobicity or affinity), etc. obtained through various additional purification methods It is also possible to obtain a fermented extract of brown mealworm larvae through fractionation.
본 발명의 갈색거저리 유충 발효 추출물은 추출, 분획, 또는 정제(분리, 분획)의 각 단계에서 얻어지는 모든 추출액, 분획, 정제물, 그들의 희석액, 농축액, 또는 건조물일 수 있다.The brown mealworm larva ferment extract of the present invention may be all extracts, fractions, purified products, dilutions, concentrates, or dried products obtained in each step of extraction, fractionation, or purification (separation, fractionation).
본 발명에 있어서, 상기 "유효성분"이란 단독으로 목적하는 활성을 나타내거나 또는 그 자체는 활성이 없는 담체와 함께 활성을 나타낼 수 있는 성분을 의미한다.In the present invention, the "active ingredient" refers to a component that can exhibit the desired activity alone or can exhibit activity together with a carrier that does not have the activity itself.
본 발명에서 사용되는 용어 "골다공증"이란 뼈의 주성분인 칼슘이 급격히 빠져나와 정상적인 뼈에 비하여 골밀도가 낮아져 "구멍이 많이 난 뼈"를 말하며, 폐경, 노화, 뼈에 해로운 약물의 사용 등의 여러 가지 원인에 의하여 뼈가 많이 손실되고 약해져 경미한 충격에도 쉽게 골절이 일어나는 질환이다.As used herein, the term “osteoporosis” refers to “perforated bone” due to the rapid escape of calcium, the main component of bone, and lower bone density compared to normal bone. It is a disease in which a lot of bone is lost and weak due to causes, and fractures occur easily even with a slight impact.
본 발명에서 사용되는 용어 "예방"이란, 본 발명에 따른 갈색거저리 유충 발효 추출물을 개체에 투여하여 골다공증의 발병을 억제하거나 지연시키는 모든 행위를 의미할 수 있다.The term "prevention" used in the present invention may refer to any action that suppresses or delays the onset of osteoporosis by administering the fermented brown mealworm larvae extract according to the present invention to an individual.
본 발명에서 사용되는 용어 "치료" 또는 "개선"이란, 본 발명의 상기 조성물을 골다공증 발병 의심 개체에 투여하여 골다공증의 증세가 호전되도록 하거나 이롭게 되도록 하는 모든 행위를 의미할 수 있다.The term "treatment" or "improvement" used in the present invention may refer to any action to improve or benefit the symptoms of osteoporosis by administering the composition of the present invention to a subject suspected of having osteoporosis.
본 발명의 약학적 조성물은 파골세포를 억제시키고 조골세포를 촉진시키는 것일 수 있으나, 이에 제한되지 않는다.The pharmaceutical composition of the present invention may be to inhibit osteoclasts and promote osteoblasts, but is not limited thereto.
본 발명에서 사용되는 용어 "파골세포(osteoclast)"란, 대식 세포 전구체(macrophage precursor)로부터 파생되는 세포로서, 파골세포 전구 세포들은 대식세포 콜로니 자극 인자(macrophage colony stimulating factor, M-CSF), NF-κB의 수용체 활성 인자 리간드(RANKL) 등에 의해 파골세포로 분화되며 융합을 통해 다핵파골세포(multinucleated osteoclast)를 형성한다. 파골세포는 αvβ3 인테그린(integrin) 등을 통해 골(bone)에 결합하며 산성 환경을 조성하는 한편 각종 콜라게네이즈(collagenase) 및 프로테아제(protease)를 분비하여 골 흡수(bone resorption)를 일으킨다. 파골세포는 완전히 분화된 세포로 증식하지 않으며 약 2 주간의 수명이 다하면 세포 사멸(apotosis)를 일으킨다.As used herein, the term "osteoclast" is a cell derived from a macrophage precursor, and the osteoclast precursor cells are macrophage colony stimulating factor (M-CSF), NF It differentiates into osteoclasts by -κB receptor activator ligand (RANKL), etc., and forms multinucleated osteoclasts through fusion. Osteoclasts bind to bone through αvβ3 integrin, etc. and create an acidic environment, while secreting various collagenases and proteases to cause bone resorption. Osteoclasts do not proliferate into fully differentiated cells and cause apoptosis at the end of their life span of about 2 weeks.
본 발명에서 사용되는 용어 "조골세포(osteoblast)"란, 중간엽줄기세포에서부터 분화하여 생성되는 세포로 골질을 만들어 골밀도를 증가시키는 역할을 하며, 때로는 조골세포의 활성이 과도하게 증가되면 골밀도가 증가되어 뼈의 기형이나 골 석화증 등을 일어나게 한다.As used herein, the term "osteoblast" is a cell produced by differentiation from mesenchymal stem cells, and serves to increase bone density by making bone mass, and sometimes when the activity of osteoblasts is excessively increased, bone density increases. This can lead to bone deformities or osteopetrosis.
본 발명의 일 실시예에서는 파골세포로 분화한 골수 세포에 갈색거저리 유충 발효 추출물을 처리한 후, 파골세포 분화 표지 인자인 TRAP(tarrateresistant acid phosphate) 염색을 실시한 결과, TRAP 활성을 농도 의존적으로 저해시키는 것을 확인하였다(도 1). 이와 같이 본 발명에 따른 갈색거저리 유충 발효 추출물을 유효성분으로 포함하는 조성물은 TRAP 활성 억제를 통해 파골세포의 분화를 효과적으로 억제하므로, 파골세포의 활성 증가에 의한 골다공증과 같은 대사성 골질환을 예방 또는 치료할 수 있다.In one embodiment of the present invention, after treatment with the ferment extract of brown mealworm larvae in bone marrow cells differentiated into osteoclasts, tarrateresistant acid phosphate (TRAP), a marker for osteoclast differentiation, is stained. As a result, TRAP activity is inhibited in a concentration-dependent manner was confirmed (FIG. 1). As such, the composition comprising the fermented brown mealworm larvae extract according to the present invention as an active ingredient effectively inhibits the differentiation of osteoclasts through inhibition of TRAP activity. can
본 발명의 일 실시예에서 갈색거저리 유충 발효 추출물을 조골세포에 처리한 후, 골형성의 지표가 되는 효소인 ALP(alkaline phosphatase)의 활성이 증가되므로 조골세포의 분화를 촉진시킨다는 것을 확인할 수 있었다(도 2).In an embodiment of the present invention, it was confirmed that, after treatment of the fermented brown mealworm larvae extract on osteoblasts, the activity of ALP (alkaline phosphatase), an enzyme that is an indicator of bone formation, was increased, thus promoting the differentiation of osteoblasts ( Fig. 2).
이와 같은 결과는 본 발명의 조성물이 세포 수준에서 조골세포의 분화를 촉진시킬 수 있음을 입증함으로써, 본 발명의 조성물이 조골세포의 분화 또는 활성을 촉진시켜 골다공증과 같은 대사성 골질환의 예방 또는 치료 효과가 있음을 뒷받침하는 것이다.These results demonstrate that the composition of the present invention can promote the differentiation of osteoblasts at the cellular level, so that the composition of the present invention promotes the differentiation or activity of osteoblasts, thereby preventing or treating metabolic bone diseases such as osteoporosis. to support the existence of
본 발명의 약학 조성물은 단일제제로도 사용할 수 있고, 공인된 골다공증 치료 효과를 가진다고 알려진 약물을 추가로 포함하여 복합제제로 제조하여 사용할 수 있으며, 약제학적으로 허용되는 담체 또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 다용량 용기 내에 내입시켜 제조될 수 있다.The pharmaceutical composition of the present invention can be used as a single agent, and can be prepared and used as a combined formulation by additionally including a drug known to have an approved osteoporosis treatment effect, and a unit dose by formulation using a pharmaceutically acceptable carrier or excipient. It may be manufactured in a form or by being introduced into a multi-dose container.
또한, 필요한 경우 항산화제, 완충액 및/또는 정균제 등 다른 통상의 첨가제를 첨가하여 사용할 수 있으며, 희석제, 분산제, 계면 활성제, 결합제, 윤활제 등을 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제 등으로 제제화하여 사용할 수 있다.In addition, if necessary, other conventional additives such as antioxidants, buffers and/or bacteriostats can be added and used, and diluents, dispersants, surfactants, binders, lubricants, etc. It can be used by formulating it into a dosage form, pill, capsule, granule, or tablet.
또한, 본 발명의 약학적 조성물은 약제학적으로 유효한 양의 갈색거저리 유충 발효 추출물을 포함할 수 있다. 본 발명에서 용어, "약제학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 일반적으로 0.001 내지 1000 mg/kg의 양, 바람직하게는 0.05 내지 200 mg/kg, 보다 바람직하게는 0.1 내지 100 mg/kg의 양을 일일 1회 내지 수회로 나누어 투여할 수 있다. 그러나 본 발명의 목적상, 특정 환자에 대한 구체적인 치료적 유효량은 달성하고자 하는 반응의 종류와 정도, 경우에 따라 다른 제제가 사용되는지의 여부를 비롯한 구체적 조성물, 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 조성물의 분비율, 치료기간, 구체적 조성물과 함께 사용되거나 동시 사용되는 약물을 비롯한 다양한 인자와 의약 분야에 잘 알려진 유사 인자에 따라 다르게 적용하는 것이 바람직하다.In addition, the pharmaceutical composition of the present invention may include a pharmaceutically effective amount of fermented mealworm larvae extract. As used herein, the term "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and is generally in an amount of 0.001 to 1000 mg/kg, preferably 0.05 to 200 mg/kg, more preferably 0.1 to 100 mg/kg, may be administered once a day or divided into several times a day. However, for the purposes of the present invention, a specific therapeutically effective amount for a particular patient depends on the type and extent of the response to be achieved, the specific composition, including whether other agents are used, if necessary, the specific composition, the patient's age, weight, general health, It is preferable to apply differently depending on various factors including sex and diet, administration time, administration route and secretion rate of the composition, treatment period, drugs used together or concurrently with a specific composition, and similar factors well known in the pharmaceutical field.
본 발명의 약학적 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여할 수 있다. 그리고 단일 또는 다중 투여될 수 있다. 상기 요소를 모두 고려하여 부작용을 유발하지 않으면서 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 당업자에 의해 용이하게 결정될 수 있다.The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or may be administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. and may be administered single or multiple. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect with a minimum amount without causing side effects, and can be easily determined by those skilled in the art.
본 발명에 따른 약학 조성물의 투여 방식은 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용하는 방식에 따를 수 있다. 상기 투여 방식의 비제한적인 예로, 조성물을 경구 투여 또는 비경구 투여 방식으로 투여할 수 있다. 본 발명에 따른 약학 조성물은 목적하는 투여 방식에 따라 다양한 제형으로 제작될 수 있다.The method of administration of the pharmaceutical composition according to the present invention is not particularly limited, and may follow a method commonly used in the art. As a non-limiting example of the administration method, the composition may be administered by oral administration or parenteral administration. The pharmaceutical composition according to the present invention may be prepared in various dosage forms depending on the desired administration method.
본 발명의 조성물의 투여빈도는 특별히 이에 제한되지 않으나, 1일 1회 투여하거나 또는 용량을 분할하여 수회 투여할 수 있다.The administration frequency of the composition of the present invention is not particularly limited thereto, but may be administered once a day or administered several times by dividing the dose.
본 발명의 조성물에는 갈색거저리 유충 발효 추출물이 조성물의 총 중량을 기준으로 하여 0.005 내지 50 중량%, 보다 바람직하게는 0.01 내지 30 중량%, 가장 바람직하게는 0.1 내지 10 중량%로 포함할 수 있다. 이때, 갈색거저리 유충 발효 추출물의 함량이 0.005 중량% 미만일 경우 본 발명의 목적 효과인 항골다공증 효과를 수득할 수 없으며, 50 중량%를 초과할 경우 함량의 증가에 따라 효과가 비례적이지 않아 비효율적일 수 있으며 제형상의 안정성이 확보되지 않는 문제점이 있다.The composition of the present invention may contain 0.005 to 50% by weight, more preferably 0.01 to 30% by weight, and most preferably 0.1 to 10% by weight of the brown mealworm larva ferment extract based on the total weight of the composition. At this time, if the content of the brown mealworm larva ferment extract is less than 0.005% by weight, the anti-osteoporosis effect, which is the objective effect of the present invention, cannot be obtained, and if it exceeds 50% by weight, the effect is not proportional to the increase in the content, so it will be inefficient and there is a problem in that stability in formulation is not secured.
본 발명의 갈색거저리 유충 발효 추출물을 함유하는 조성물은 항골다공증 효과를 나타내며, 천연 물질로서 세포독성이 거의 없다.The composition containing the fermented brown mealworm larvae extract of the present invention exhibits an antiosteoporotic effect, and has little cytotoxicity as a natural material.
다른 하나의 양태로서, 본 발명은 갈색거저리 유충 발효 추출물을 유효성분으로 포함하는 골다공증 예방 또는 개선용 건강기능식품 조성물을 제공한다.As another aspect, the present invention provides a health functional food composition for preventing or improving osteoporosis comprising the fermented brown mealworm larvae extract as an active ingredient.
상기 골다공증은 상기한 바와 같다. 상기 갈색거저리 유충 발효 추출물은 천연 물질로서 오랫동안 사용되어 안정성이 입증되었으므로, 상식할 수 있으면서도 골다공증의 예방 또는 개선을 도모할 수 있는 식품의 형태로 제조되어 섭취할 수 있다. The osteoporosis is as described above. Since the fermented brown mealworm larvae extract has been used for a long time as a natural material and has proven stability, it can be prepared and consumed in the form of food that can promote the prevention or improvement of osteoporosis while being common knowledge.
본 발명에서 사용되는 용어 "건강기능식품"이란, 건강보조의 목적으로 특정 성분을 원료로 하거나 식품 원료에 들어 있는 특정 성분을 추출, 농축, 정제, 혼합 등의 방법으로 제조, 가공한 식품을 말하며, 상기 성분에 의해 생체방어, 생체리듬의 조절, 질병의 방지와 회복 등 생체조절기능을 생체에 대하여 충분히 발휘할 수 있도록 설계되고 가공된 식품을 말하는 것으로서, 상기 건강식품용 조성물은 질병의 예방 및 질병의 회복 등과 관련된 기능을 수행할 수 있다. 상기 식품은 골다공증의 예방 또는 개선에 유용한 효과를 얻기 위하여 정제, 캡슐, 분말, 과립, 액상, 환 등의 다양한 형태로 제조될 수 있다.The term "health functional food" used in the present invention refers to a food manufactured and processed using a specific ingredient as a raw material for the purpose of health supplementation, or by extracting, concentrating, refining, or mixing a specific ingredient contained in a food raw material. , refers to a food designed and processed to sufficiently exert biological control functions such as biological defense, regulation of biological rhythm, prevention and recovery of disease, etc., with the above ingredients, and the composition for health food is used for disease prevention and disease prevention It can perform functions related to recovery, etc. The food may be prepared in various forms such as tablets, capsules, powders, granules, liquids, pills, etc. in order to obtain a useful effect in preventing or improving osteoporosis.
또한, 본 발명의 조성물이 사용될 수 있는 건강기능식품의 종류에는 제한이 없다. 아울러 본 발명의 갈색거저리 유충 발효 추출물을 유효성분으로 포함하는 조성물은 당업자의 선택에 따라 건강기능식품에 함유될 수 있는 적절한 기타 보조 성분과 공지의 첨가제를 혼합하여 제조할 수 있다. 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 본 발명에 따른 갈색거저리 유충 발효 추출물을 주성분으로 하여 제조한 즙, 차, 젤리 및 주스 등에 첨가하여 제조할 수 있다.In addition, there is no limitation on the type of health functional food in which the composition of the present invention can be used. In addition, the composition comprising the fermented brown mealworm larvae extract of the present invention as an active ingredient can be prepared by mixing known additives with other suitable auxiliary ingredients that may be contained in health functional foods according to the selection of those skilled in the art. Examples of foods that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages and There are vitamin complexes and the like, and it can be prepared by adding the fermented extract of brown mealworm larvae according to the present invention as a main component to juice, tea, jelly, juice, and the like.
본 발명의 식품 조성물은 식품학적으로 허용가능한 담체를 추가로 포함하는 것일 수 있다.The food composition of the present invention may further include a food pharmaceutically acceptable carrier.
본 발명의 갈색거저리 유충 발효 추출물을 포함하는 조성물을 첨가할 수 있는 식품의 종류에는 별다른 제한이 없으며, 예를 들어 각종 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있다. 상기 식품 조성물에는 골다공증의 예방 또는 개선 효과에 방해가 되지 않는 다른 성분을 추가할 수 있으며, 그 종류는 특별히 제한되지 않는다. 예를 들어, 통상의 식품과 같이 여러 가지 생약 추출물, 식품학적으로 허용 가능한 식품보조첨가제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.There is no particular limitation on the type of food to which the composition containing the fermented brown mealworm larvae extract of the present invention can be added, for example, various beverages, gum, tea, vitamin complexes, health supplements, and the like. Other ingredients that do not interfere with the prevention or improvement effect of osteoporosis may be added to the food composition, and the type thereof is not particularly limited. For example, it may contain various herbal extracts, food-logically acceptable food supplements or natural carbohydrates as additional ingredients, such as conventional food.
상기 식품보조첨가제는 각 제형의 건강기능식품을 제조하는데 첨가되는 것으로서 당업자가 적절히 선택하여 사용할 수 있다. 예를 들어 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 충진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등이 포함되지만, 상기 예들에 의해 그 종류가 제한되는 것은 아니다.The food supplement additive is added to the production of health functional food of each formulation, and those skilled in the art can appropriately select and use it. For example, various nutrients, vitamins, minerals (electrolytes), synthetic flavoring agents and flavoring agents such as natural flavoring agents, coloring agents and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusting agents , stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated drinks, and the like, but the types are not limited by the above examples.
이때, 상기 식품에 포함되는 추출물의 함량은 특별히 이에 제한되지 않으나, 식품 조성물의 총 중량에 대하여 0.01 내지 100 중량%, 바람직하게는 0.005 내지 50 중량%, 보다 바람직하게는 0.01 내지 30 중량%, 가장 바람직하게는 0.1 내지 10 중량%로 포함할 수 있다.At this time, the content of the extract contained in the food is not particularly limited thereto, but 0.01 to 100% by weight, preferably 0.005 to 50% by weight, more preferably 0.01 to 30% by weight, most of the total weight of the food composition. Preferably, it may be included in an amount of 0.1 to 10% by weight.
식품이 음료인 경우에는 100 ㎖를 기준으로 1 내지 30g, 바람직하게는 3 내지 20g의 비율로 포함될 수 있다. 또한, 상기 조성물은 식품 조성물에 통상 사용되어 냄새, 맛, 시각 등을 향상시킬 수 있는 추가 성분을 포함할 수 있다. 예를 들어, 비타민 A, C, D, E, B1, B2, B6, B12, 니아신(niacin), 비오틴(biotin), 폴레이트(folate), 판토텐산(panthotenic acid) 등을 포함할 수 있다. 또한, 아연(Zn), 철(Fe), 칼슘(Ca), 크롬(Cr), 마그네슘(Mg), 망간(Mn), 구리(Cu) 등의 미네랄을 포함할 수 있다. 또한, 라이신, 트립토판, 시스테인, 발린 등의 아미노산을 포함할 수 있다. 또한, 방부제(소르빈산 칼륨, 벤조산나트륨, 살리실산, 데히드로초산나트륨 등), 살균제(표백분과 고도 표백분, 차아염소산나트륨 등), 산화방지제(부틸히드록시아니졸(BHA), 부틸히드록시톨류엔(BHT) 등), 착색제(타르색소 등), 발색제(아질산 나트륨, 아초산 나트륨 등), 표백제(아황산나트륨), 조미료(MSG 글루타민산나트륨 등), 감미료(둘신, 사이클레메이트, 사카린, 나트륨 등), 향료(바닐린, 락톤류 등), 팽창제(명반, D-주석산수소칼륨 등), 강화제, 유화제, 증점제(호료), 피막제, 검기초제, 거품억제제, 용제, 개량제 등의 식품 첨가물(food additives)을 첨가할 수 있다. 상기 첨가물은 식품의 종류에 따라 선별되고 적절한 양으로 사용된다.When the food is a beverage, it may be included in a ratio of 1 to 30 g, preferably 3 to 20 g, based on 100 ml. In addition, the composition may include additional ingredients that are commonly used in food compositions to improve odor, taste, vision, and the like. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, pantothenic acid, and the like may be included. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu). In addition, it may include amino acids such as lysine, tryptophan, cysteine, and valine. In addition, preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), disinfectants (bleaching powder and high bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisole (BHA), butylhydroxytoluene ( BHT), etc.), colorant (tar pigment, etc.), color developer (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasoning (MSG sodium glutamate, etc.), sweetener (dulcin, cyclmate, saccharin, sodium, etc.) , flavorings (vanillin, lactones, etc.), bulking agents (alum, D-potassium hydrogen tartrate, etc.), strengthening agents, emulsifiers, thickeners (flavors), film agents, gum base agents, foam suppressants, solvents, food additives such as improving agents ) can be added. The additive is selected according to the type of food and used in an appropriate amount.
본 발명의 건강기능성 식품은 당업계에서 통상적으로 사용되는 방법에 의하여 제조가능하며, 상기 제조 시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어날 수 있다.The health functional food of the present invention can be prepared by a method commonly used in the art, and during the manufacture, it can be prepared by adding raw materials and components commonly added in the art. In addition, unlike general drugs, there are no side effects that may occur when taking the drug for a long time by using food as a raw material, and it can be excellent in portability.
한편, 본 발명의 갈색거저리 유충 발효 추출물은 천연물질로서 인체에 무해하며, 독성 및 부작용이 거의 없으므로 장기간 사용시에도 안심하고 사용할 수 있으며, 특히 상기한 바와 같은 약학적 및 식품 조성물에 안전하게 적용할 수 있다.On the other hand, the fermented brown mealworm larvae extract of the present invention is a natural material, harmless to the human body, and has almost no toxicity and side effects, so it can be safely used even for long-term use, and in particular, it can be safely applied to pharmaceutical and food compositions as described above. .
또 다른 하나의 양태로서, 본 발명은 갈색거저리 유충 발효 추출물을 인간을 제외한 개체에 투여하는 단계를 포함하는 골다공증 예방 또는 치료 방법을 제공한다.As another aspect, the present invention provides a method for preventing or treating osteoporosis, comprising administering a fermented extract of Mealworm larvae to individuals other than humans.
본 발명에서 사용되는 용어 "개체"란, 골다공증이 발병되었거나 발병할 가능성이 있는 인간을 포함한 모든 동물을 의미할 수 있다. 상기 동물은 인간뿐만 아니라 이와 유사한 증상의 치료를 필요로 하는 소, 말, 양, 돼지, 염소, 낙타, 영양, 개, 고양이 등의 포유동물일 수 있으나, 이에 제한되지는 않는다.As used herein, the term “individual” may refer to any animal, including humans, that has or is likely to develop osteoporosis. The animal may be a mammal, such as a cow, a horse, a sheep, a pig, a goat, a camel, an antelope, a dog, or a cat, in need of treatment for symptoms similar to those of a human as well as humans, but is not limited thereto.
본 발명의 상기 예방 또는 치료 방법은 구체적으로, 골다공증이 발병하였거나 발병할 위험이 있는 개체에 상기 조성물을 약학적으로 유효한 양으로 투여하는 단계를 포함할 수 있다.Specifically, the prevention or treatment method of the present invention may include administering the composition in a pharmaceutically effective amount to an individual who has or is at risk of developing osteoporosis.
본 발명에서 사용되는 용어 "투여"는 어떠한 적절한 방법으로 환자에게 본 발명의 약학적 조성물을 도입하는 것을 의미하며, 본 발명의 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 경구 또는 비경구의 다양한 경로를 통하여 투여될 수 있다.The term "administration" as used in the present invention means introducing the pharmaceutical composition of the present invention to a patient by any suitable method, and the administration route of the composition of the present invention may be oral or parenteral as long as it can reach the target tissue. It may be administered via a route.
이하, 실시예를 통하여 본 발명의 구성 및 효과를 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것일 뿐, 본 발명의 범위가 이들 실시예에 의해 한정되는 것은 아니다.Hereinafter, the configuration and effects of the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and the scope of the present invention is not limited by these examples.
실시예 1: 갈색거저리 유충 발효 추출물의 제조Example 1: Preparation of Mealworm Larva Fermented Extract
식품공전의 유기물질 추출방법인 유기용매(헥산)추출법을 이용하여 갈색거저리 유충을 24시간 용매(헥산) 추출하여 유지 및 오일 성분을 분리하였다. 여과 후 남은 갈색거저리 유충을 잔류 헥산을 제거하고 건조한 후 파쇄기로 파쇄하여 탈지된 갈색거저리 유충 분말을 제조하였다.Using the organic solvent (hexane) extraction method, which is an organic material extraction method of the food industry, the brown mealworm larvae were extracted with a solvent (hexane) for 24 hours to separate the oil and fat components. After filtration, residual hexane was removed from the remaining brown mealworm larvae, dried, and crushed with a crusher to prepare defatted brown mealworm larvae powder.
갈색거저리 유충 발효 추출물은 총 150 L 발효 기준으로 이스트 1.5 kg, 덱스트로스 3.0 kg, 및 상기 탈지된 갈색거저리 유충 분말 3.0 kg을 넣은 후 100℃에서 45분간 멸균하고 33℃로 냉각하였다. 이후 사카로마이세스 세레비지애(saccharomyces cerevisiae) 균주 15 mL을 접종하고 30±4℃에서 72시간 동안 효모 발효를 진행하여 탈지 갈색거저리 유충 발효 배양액을 제조하였다.After adding 1.5 kg of yeast, 3.0 kg of dextrose, and 3.0 kg of the defatted mealworm larvae powder to a total of 150 L fermentation extract, the fermented extract was sterilized at 100° C. for 45 minutes and cooled to 33° C. Then, Saccharomyces cerevisiae ( saccharomyces cerevisiae ) strain 15 mL was inoculated and yeast fermentation was performed at 30 ± 4 ° C for 72 hours to prepare a defatted brown mealworm larvae fermentation broth.
한편, 대조군인 갈색거저리 유충 비발효 추출물은 발효 과정을 제외하고 발효 추출물과 동일하게 제조 및 추출하였다.On the other hand, the non-fermented extract of brown mealworm larvae as a control group was prepared and extracted in the same manner as the fermented extract except for the fermentation process.
상기 탈지 갈색거저리 유충 발효 배양액 300 L에 70% 주정 700 L를 혼합한 후 95℃에서 3시간 가열 추출을 진행한 다음 추출물을 부직포 여과 필터를 통과시켜 이물질을 제거하고 산업용 고온감압농축기를 사용하여 12~13 Brix(%)가 확인된 시점에서 농축을 종료하였다.After mixing 700 L of 70% alcohol with 300 L of the defatted brown mealworm larvae fermentation broth, heat extraction at 95° C. for 3 hours, and then pass the extract through a non-woven filter filter to remove foreign substances and use an industrial high-temperature decompression concentrator. Concentration was terminated at the point when -13 Brix (%) was confirmed.
제조된 발효 및 비발효 추출 농축물은 -40℃ 냉동고에 동결시킨 후 산업용 동결건조기로 동결건조하여 분말 제형으로 만든 후 진공 포장하여 보관하고, 이후 실험에 사용하였다.The prepared fermented and non-fermented extract concentrate was frozen in a -40°C freezer and then lyophilized with an industrial freeze dryer to make a powder formulation, then vacuum-packed and stored, and then used for subsequent experiments.
실시예 2: 갈색거저리 유충 발효 추출물에 의한 파골세포의 분화 억제 효과Example 2: Effect of inhibiting differentiation of osteoclasts by fermented brown mealworm larvae extract
갈색거저리 유충 발효 추출물이 파골세포 분화에 미치는 영향을 확인하고자, 파골세포에 갈색거저리 유충 발효 추출물을 처리한 후, TRAP(Tartrate-resistant acid phosphatase) 염색하여 갈색거저리 유충 발효 추출물에 의한 파골세포의 분화 정도를 확인하였다.In order to confirm the effect of fermented brown mealworm larvae extract on osteoclast differentiation, osteoclasts were treated with brown mealworm larvae ferment extract and then TRAP (Tartrate-resistant acid phosphatase) stained to differentiate osteoclasts by brown mealworm larvae fermented extract. The degree was confirmed.
구체적으로, 골수세포는 5~6주령 수컷 마우스의 정강이뼈와 대퇴골로부터 채취하였다. 골수세포는 10% FBS(fetal bovine serum), 100 units/mL 페니실린(penicillin), 10 ng/mL M-CSF가 첨가된 a-MEM(minimum essential medium eagle-alpha modification) 배지를 이용하여 96웰 플레이트에 1×104 cells/well로 깔고 24시간 동안 배양하였다. 다음 날 10 ng/mL RANKL, 30 ng/mL M-CSF와 대조 비히클(control vehicle) 또는 농도별 갈색거저리 유충의 발효 추출물 및 비발효 추출물을 첨가하여 4일간 배양함으로써 분화를 진행하였다.Specifically, bone marrow cells were collected from the shin bones and femurs of 5-6 week old male mice. Bone marrow cells were prepared in a 96-well plate using a-MEM (minimum essential medium eagle-alpha modification) medium supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin, and 10 ng/mL M-CSF. 1 × 10 4 cells/well was spread on the bed and cultured for 24 hours. The next day, 10 ng/mL RANKL, 30 ng/mL M-CSF and a control vehicle or concentration-specific fermented and non-fermented extracts of brown mealworm larvae were added, followed by culturing for 4 days.
이후, 세포는 PBS로 세척하고 3.7% 포르말린으로 5분간 고정하였다. 고정된 세포는 0.1% Triton X-100으로 10분 동안 반응시킨 후 TRAP 용액을 처리해 37℃, 암실에서 10분간 반응시켰다. TRAP 염색한 세포는 광학현미경을 이용하여 200배 비율로 관찰하였다.Then, the cells were washed with PBS and fixed with 3.7% formalin for 5 minutes. The fixed cells were reacted with 0.1% Triton X-100 for 10 minutes, then treated with TRAP solution and reacted for 10 minutes at 37°C in the dark. TRAP-stained cells were observed at a 200-fold ratio using an optical microscope.
그 결과, 갈색거저리 유충 발효 추출물은 농도 의존적으로 파골세포 분화를 억제하였으며, 특히, 10 ㎍/mL 농도부터 파골세포 분화 억제 효과가 우수한 것으로 확인되었다. 모든 처리 농도에서 갈색거저리 유충 비발효 추출물에 비하여 갈색거저리 유충 발효 추출물의 파골세포 분화 억제 효과가 우수하였다(도 1).As a result, the fermented brown mealworm larvae extract inhibited osteoclast differentiation in a concentration-dependent manner, and in particular, it was confirmed that the osteoclast differentiation inhibitory effect was excellent from the concentration of 10 μg/mL. At all treatment concentrations, the osteoclast differentiation inhibitory effect of the fermented Mealworm larvae extract was superior to that of the non-fermented extract of Mealworm larvae (FIG. 1).
실시예 3: 갈색거저리 유충 발효 추출물에 의한 조골세포의 분화 촉진 효과Example 3: Effect of promoting differentiation of osteoblasts by the fermented brown mealworm larvae extract
갈색거저리 유충 발효 추출물이 조골세포 분화에 미치는 영향을 확인하고자, 조골세포에 갈색거저리 유충 발효 추출물을 처리한 후, ALP(Alkaline phosphatase) 염색하여 갈색거저리 유충 발효 추출물에 의한 조골세포의 분화 정도를 확인하였다.In order to confirm the effect of the brown mealworm larvae fermented extract on osteoblast differentiation, osteoblasts were treated with the brown mealworm larvae fermented extract, followed by ALP (Alkaline phosphatase) staining to determine the degree of differentiation of osteoblasts by the brown mealworm larvae fermented extract. did
구체적으로, C2C12 세포는 5% FBS, 100 units/mL 페니실린이 첨가된 DMEM 배지를 이용하여 96웰 플레이트에 5×103 cells/well로 깔고 24시간 동안 배양하였다. 다음 날 100 ng/mL BMP-2와 대조 비히클(control vehicle) 또는 농도별 갈색거저리 유충의 발효 추출물 및 비발효 추출물을 첨가하여 4일간 배양함으로써 분화를 진행하였다.Specifically, C2C12 cells were spread in a 96-well plate at 5×10 3 cells/well using DMEM medium supplemented with 5% FBS and 100 units/mL penicillin and cultured for 24 hours. The next day, 100 ng/mL BMP-2 and a control vehicle or a fermented extract and a non-fermented extract of brown mealworm larvae for each concentration were added, and differentiation was carried out by culturing for 4 days.
이후, 상기 분화를 진행한 세포는 PBS로 세척하고 3.7% 포르말린으로 2분간 고정하였다. 고정된 세포는 ALP 염색 용액을 처리해 37℃, 암실에서 염색한 후 광학현미경을 이용하여 200배 비율로 관찰하였다.Thereafter, the differentiated cells were washed with PBS and fixed with 3.7% formalin for 2 minutes. The fixed cells were treated with ALP staining solution and stained at 37° C. in a dark room, and then observed at a 200-fold ratio using an optical microscope.
그 결과, 갈색거저리 유충 발효 추출물은 농도 의존적으로 조골세포 분화를 촉진하였으며, 3 ㎍/mL 농도부터 활성이 확연히 증가됨을 보였다. 모든 처리 농도에서 갈색거저리 유충 비발효 추출물에 비하여 갈색거저리 유충 발효 추출물의 조골세포 분화 촉진 활성이 우수하였다(도 2).As a result, the fermented brown mealworm larvae extract promoted osteoblast differentiation in a concentration-dependent manner, and showed a marked increase in activity from the concentration of 3 μg/mL. In all treatment concentrations, the osteoblast differentiation promoting activity of the fermented Mealworm larvae extract was superior to that of the non-fermented extract of Mealworm larvae (FIG. 2).
Claims (6)
A pharmaceutical composition for preventing or treating osteoporosis comprising a fermented brown mealworm larvae extract as an active ingredient.
The method of claim 1, wherein the fermented extract is extracted using an organic solvent to remove the fat and oil and fat components contained in the brown mealworm larvae, and then dried, fermented using a fermented strain, and extracted using water or an organic solvent. Which is obtained by, the pharmaceutical composition.
The pharmaceutical composition according to claim 2, wherein the fermentation strain is a Saccharomyces cerevisiae strain.
The pharmaceutical composition of claim 1, wherein the composition exhibits osteoclast inhibition and osteoblast promoting effects.
The pharmaceutical composition according to claim 1, wherein the fermented mealworm extract is included in an amount of 0.005 to 50% by weight based on the total weight of the composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200099392A KR102379612B1 (en) | 2020-08-07 | 2020-08-07 | Composition for preventing and treating osteoporosis comprising extracts of fermented tenebrio molitor larva |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200099392A KR102379612B1 (en) | 2020-08-07 | 2020-08-07 | Composition for preventing and treating osteoporosis comprising extracts of fermented tenebrio molitor larva |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220018822A true KR20220018822A (en) | 2022-02-15 |
| KR102379612B1 KR102379612B1 (en) | 2022-03-29 |
Family
ID=80325742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200099392A KR102379612B1 (en) | 2020-08-07 | 2020-08-07 | Composition for preventing and treating osteoporosis comprising extracts of fermented tenebrio molitor larva |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102379612B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102555674B1 (en) * | 2022-11-04 | 2023-07-18 | 주식회사 한미양행 | Composition containing Tenebrio molitor and Protaetia larva brevitarsis larva enzymatic hydrolysate for preventing or treating menopausal symptom |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101404566B1 (en) | 2012-11-09 | 2014-06-11 | 동아대학교 산학협력단 | Composition for preventing or treating dementia comprising Tenebrio molitor extract |
| KR101424125B1 (en) | 2012-11-09 | 2014-08-04 | 대한민국 | Composition for treating inflammatory disease comprising Tenebrio molitor larvae |
| KR101651908B1 (en) | 2014-10-06 | 2016-08-30 | 대한민국 | Composition for Prevention or Treatment diabetes comprising Tenebrio molitor larva or extract suspension of Tenebrio molitor larva |
| KR101651907B1 (en) | 2014-10-06 | 2016-09-12 | 대한민국 | Composition for Prevention or Treatment of Obesity Comprising Tenebrio molitor larva extract or Tenebrio molitor larva suspension |
| KR20190060511A (en) * | 2017-11-24 | 2019-06-03 | (재) 순천천연물의약소재개발연구센터 | A composition for antioxidating comprising extracts of fermented tenebrio molitor |
-
2020
- 2020-08-07 KR KR1020200099392A patent/KR102379612B1/en active IP Right Grant
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101404566B1 (en) | 2012-11-09 | 2014-06-11 | 동아대학교 산학협력단 | Composition for preventing or treating dementia comprising Tenebrio molitor extract |
| KR101424125B1 (en) | 2012-11-09 | 2014-08-04 | 대한민국 | Composition for treating inflammatory disease comprising Tenebrio molitor larvae |
| KR101651908B1 (en) | 2014-10-06 | 2016-08-30 | 대한민국 | Composition for Prevention or Treatment diabetes comprising Tenebrio molitor larva or extract suspension of Tenebrio molitor larva |
| KR101651907B1 (en) | 2014-10-06 | 2016-09-12 | 대한민국 | Composition for Prevention or Treatment of Obesity Comprising Tenebrio molitor larva extract or Tenebrio molitor larva suspension |
| KR20190060511A (en) * | 2017-11-24 | 2019-06-03 | (재) 순천천연물의약소재개발연구센터 | A composition for antioxidating comprising extracts of fermented tenebrio molitor |
Non-Patent Citations (3)
| Title |
|---|
| Jingu Lee et al. Health-enhancing Effects of feed supplemented with mealworm(Tenebrio molitor) on dog. Proceedings of the Korean Society of Applied Entomology Conference. Vol. 2019, No. 04, 2019, pp. 154 * |
| Minchul Seo et al. Osteoblastogenic Activity of Tenebrio molitor Larvae Oil on the MG-63 Osteoblastic Cell. Journal of Life Science. 2019, Vol. 29(9), pp. 1027~1033* * |
| RL. Prince, et. al., N. Engl. J. Med., 325(17):1189-1195, 1991 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102555674B1 (en) * | 2022-11-04 | 2023-07-18 | 주식회사 한미양행 | Composition containing Tenebrio molitor and Protaetia larva brevitarsis larva enzymatic hydrolysate for preventing or treating menopausal symptom |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102379612B1 (en) | 2022-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101982326B1 (en) | Composition for prevention, improvement or treatment of muscular disorder or improvement of muscular functions | |
| US20120052138A1 (en) | Composition comprising green tea extract | |
| US8828955B2 (en) | Glutathione production enhancer, prophylactic/therapeutic agent for diseases caused by glutathione deficiency, and food, beverage and feed | |
| KR101651907B1 (en) | Composition for Prevention or Treatment of Obesity Comprising Tenebrio molitor larva extract or Tenebrio molitor larva suspension | |
| KR102178926B1 (en) | A composition for reinforcing immune function and anti-fatigue comprising fermented placenta and its use | |
| JP2012051940A (en) | Beverage/food and medicine comprising loquat leaf extract | |
| KR101695848B1 (en) | A composition comprising ginsenoside f2 for preventing or treating non-alcoholic liver disease | |
| KR102519649B1 (en) | Composition for the prevention or treatment of prostate-related disease comprising Rhodiola sachalinensis root extract containing kaempferol and epicatechin gallate | |
| JP2024050702A (en) | Composition for preventing or treating obesity or obesity-induced metabolic syndrome, comprising Enterococcus faecalis as an active ingredient | |
| KR102379612B1 (en) | Composition for preventing and treating osteoporosis comprising extracts of fermented tenebrio molitor larva | |
| JPWO2004112817A1 (en) | Celery family-derived extract and method for producing the same | |
| KR20210020988A (en) | Composition for stimulation of bone formation comprising xanthorrhizol as effective component | |
| KR20190052233A (en) | Composition for preventing, alleviating or treating fatty liver disease comprising extract of Tenebrio molitor as effective component | |
| KR20200140749A (en) | Composition for improvement, treatment or prevention of muscular disorders, or improvement of muscular functions comprising Cudrania tricuspidata | |
| KR102242400B1 (en) | Functional Food for preventing Composition for preventing inflammatory disease due to stress | |
| WO2019131274A1 (en) | Method for producing fermentation product derived from green tea extract, and koji fermentation product derived from green tea extract | |
| WO2018008999A1 (en) | Composition comprising aster koraiensis extract or fraction thereof as active ingredient for regulating blood glucose and preventing or treating diabetes | |
| KR20180136785A (en) | A composition for prevention and treatment of osteoporosis comprising extracts of oat hull | |
| KR102633488B1 (en) | Composition for improvement, prevention or treatment of muscular disorders, or improvement of muscular functions comprising Korean mint extract or tilianin | |
| KR101364690B1 (en) | Composition for promoting bone growth comprising bamboo | |
| KR102380295B1 (en) | A composition for preventing, improving or treating sarcopenia comprising extracts of oat | |
| KR20110078237A (en) | Composition for treating or preventing obesity containing eriobotrya japonica extract | |
| KR20220168782A (en) | A composition for prevention and treatment of osteoporosis comprising extract from Finger1ho | |
| KR101785970B1 (en) | Pharmaceutical composition for the prevention or treatment of muscle loss comprising Oleic acid or pharmaceutically acceptable salts thereof as an active ingredient | |
| KR20220142074A (en) | Composition for improving liver function comprising Cudrania tricuspidata fruit and white grub as an effective ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |